Across TCGA pan-cancer cohorts, PJA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PJA2 data layer compared with 24 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher PJA2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PJA2 expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

CCRCC, LSCC, and UCEC are the cancer types where PJA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.600	0.854	<.001	64	view →
LSCC	DFS	Median	II,III,IV	0.481	0.864	<.001	36	view →
UCEC	OS	Median	III,IV	0.433	1.000	.007	18	view →
PDAC	DFS	Quartile	II,III,IV	0.455	0.303	.012	10	view →
LUAD	DFS	Median	All	0.595	0.978	.001	10	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: PJA2 tumor-vs-normal RNA expression · all PJA2 data types